Prof. Dr.  

Kristian Reich

, Hamburg - Germany

Presentations

Real-World Experience With Apremilast: Influence of Number of Prior Conventional Systemic Therapies on Physician- and Patient-Reported Outcomes in Patients With Plaque Psoriasis During Routine Dermatology Care in Germany 10 October 2019 09:20 - 09:30
Long-term Safety of Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis: Integrated Data Through Week 156 of the Phase 3 VOYAGE 1 and VOYAGE 2 Trials 10 October 2019 10:15 - 10:25
Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from the Intent-to-Treat Population of Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) 10 October 2019 11:35 - 11:45
Time to Upadacitinib Treatment Response Over 16 Weeks for Patients with Atopic Dermatitis from a Phase 2b, Randomized, Placebo-Controlled Trial 12 October 2019 14:10 - 14:21
Absolute Psoriasis Area and Severity Index Improvement in Psoriasis Patients Treated With Guselkumab or Secukinumab: Results From the ECLIPSE Study 09 October 2019 00:00 - 00:00
Consistent Responses to Guselkumab by Geographic Region at Week 48 in the Treatment of Moderate to Severe Psoriasis: Results From the ECLIPSE Trial 09 October 2019 00:00 - 00:00
Time to relapse in patients with moderate-to-severe psoriasis who were tildrakizumab responders at week 28: post-hoc analysis through 64 weeks from reSURFACE 1 trial. 09 October 2019 00:00 - 00:00

Characterization of different psoriatic disease phenotypes based on pooled data from the extensive secukinumab phase 3 program

09 October 2019 00:00 - 00:00
Long-term Efficacy and Safety of Switching from Adalimumab to Risankizumab: Results from the Open-Label Extension LIMMitless 09 October 2019 00:00 - 00:00
Efficacy of ixekizumab versus adalimumab in psoriatic arthritis patients with moderate-to-severe psoriasis: 24-weeks results from a multicentre, randomised study 09 October 2019 00:00 - 00:00

Abstracts

Long-term Safety of Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis: Integrated Data Through Week 156 of the Phase 3 VOYAGE 1 and VOYAGE 2 Trials Psoriasis More
Absolute Psoriasis Area and Severity Index Improvement in Psoriasis Patients Treated With Guselkumab or Secukinumab: Results From the ECLIPSE Study Psoriasis More
Consistent Responses to Guselkumab by Geographic Region at Week 48 in the Treatment of Moderate to Severe Psoriasis: Results From the ECLIPSE Trial Psoriasis More

Characterization of different psoriatic disease phenotypes based on pooled data from the extensive secukinumab phase 3 program

Psoriasis More